Empagliflozin as adjunctive to insulin therapyin type 1 diabetes: The EASE trials

Julio Rosenstock, Jan Marquard, Lori M. Laffel, Dietmar Neubacher, Stefan Kaspers, David Z. Cherney, Bernard Zinman, Jay S. Skyler, Jyothis George, Nima Soleymanlou, Bruce A. Perkins

Research output: Contribution to journalArticlepeer-review

147 Scopus citations


OBJECTIVE To evaluate the safety and efficacy of empagliflozin 10- and 25-mg doses plus a unique lower dose (2.5 mg) as adjunct to intensified insulin in patients with type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS The EASE (Empagliflozin as Adjunctive to inSulin thErapy) program (N = 1,707) included two double-blind, placebo-controlled phase 3 trials: EASE-2 with empagliflozin 10 mg (n = 243), 25 mg (n = 244), and placebo (n = 243), 52-week treatment; and EASE-3 with empagliflozin 2.5 mg (n = 241), 10 mg (n = 248), 25 mg (n = 245), and placebo (n = 241), 26-week treatment. Together they evaluated empagliflozin 10 mg and 25 mg, doses currently approved in treatment of type 2 diabetes, and additionally 2.5 mg on 26-week change in glycated hemoglobin (primary end point) and weight, glucose time-in-range (>70 to £180 mg/dL), insulin dose, blood pressure, and hypoglycemia. RESULTS The observed largest mean placebo-subtracted glycated hemoglobin reductions were 20.28% (95% CI 20.42, 20.15) for 2.5 mg, 20.54% (20.65, 20.42) for 10 mg, and 20.53% (20.65, 20.42) for 25 mg (all P < 0.0001). Empagliflozin 2.5/10/25 mg doses, respectively, reduced mean weight by 21.8/23.0/23.4 kg (all P < 0.0001); increased glucose time-in-range by +1.0/+2.9/+3.1 h/day (P < 0.0001 for 10 and 25 mg); lowered total daily insulin dose by 26.4/213.3/212.7% (all P < 0.0001); and decreased systolic blood pressure by 22.1/23.9/23.7 mmHg (all P < 0.05). Genital infections occurred more frequently on empagliflozin. Adjudicated diabetic ketoacidosis occurred more with empagliflozin 10 mg (4.3%) and 25 mg (3.3%) but was comparable between empagliflozin 2.5 mg (0.8%) and placebo (1.2%). Severe hypoglycemia was rare and frequency was similar between empagliflozin and placebo. CONCLUSIONS Empagliflozin improved glycemic control and weight in T1D without increasing hypoglycemia. Ketoacidosis rate was comparable between empagliflozin 2.5 mg and placebo but increased with 10 mg and 25 mg. Ketone monitoring for early ketoacidosis detection and intervention and lower empagliflozin doses may help to reduce this risk.

Original languageEnglish (US)
Pages (from-to)2560-2569
Number of pages10
JournalDiabetes care
Issue number12
StatePublished - Dec 1 2018

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing


Dive into the research topics of 'Empagliflozin as adjunctive to insulin therapyin type 1 diabetes: The EASE trials'. Together they form a unique fingerprint.

Cite this